Skip to main content

Advertisement

SpringerLink
Log in

M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer

  • Original Article – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The m6A methylation modification is one of the most common mRNA modifications, and involved in a variety of biological processes, such as cell death, cancer stem cell formation and tumorigenesis. Increasing evidences have demonstrated that the expression patterns of m6A regulators are significantly correlated with PD-L1 level some solid tumors, but few study has explored the function of m6A regulators in the immune microenvironment and prognosis in non-small cell lung cancer (NSCLC).

Methods

Survival analysis was independently conducted for 20 m6A regulators to explore their prognostic value in NSCLC, and then the prognostic risk model based on m6A regulator expression profiles is built to stratify NSCLC patients. Also, the correlation analysis between immune infiltrating cells and m6A regulators is used to reveal the impact of m6A on immune microenvironment of NSCLC. Furthermore, to explore the function of m6A as biomarker of anit-PD-L1 therapeutic effect, we explored the associations of tumor mutation burden (TMB) and PD-L1 levels to 20 m6A regulator expression patterns in NSCLC.

Results

First, the expressions of 20 m6A regulators in NSCLC tissues were significantly increased compared to normal tissues. Survival analysis revealed that three genes, METTL3, HNRNPC and VIRMA, were markedly correlated to the prognosis of NSCLC patients. In particular, cox regression analysis verified that METTL3 could be used as an independent prognostic factor to predict the survival rate of NSCLC patients. Second, the risk prognostic model built on seven m6A regulators can effectively stratify NSCLC patients, and the low-risk subgroup had better prognosis compared to high-risk group. Finally, a few m6A regulators showed significant associations with immune microenvironment, as well as TMB and PD-L1 level, suggesting that the m6A RNA methylation is indicative of therapeutic effect of anti-PD-L1 treatment.

Conclusion

Our study identified some m6A regulatory factors as independent risk factors for the prognosis of NSCLC, and the expression patterns of m6A regulators are also correlated to the immune infiltration, as well as TMB and PD-L1 level in NSCLC. The m6A regulators could be used as biomarkers indicative of immunotherapy to NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author/s.

References

  • Alarćon CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF (2015) Hnrnpa2b1 is a mediator of m6a-dependent nuclear rna processing events. Cell 162(6):1299–1308

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Anichini A, Perotti VE, Sgambelluri F, Mortarini R (2020) Immune escape mechanisms in non small cell lung cancer. Cancers 12(12):3605

    Article  CAS  PubMed Central  Google Scholar 

  • Anita R, Paramasivam A, Priyadharsini JV, Chitra S (2020) The m6a readers ythdf1 and ythdf3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. Am J Cancer Res 10(8):2546

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M, Hüttelmaier S (2013) Insulin-like growth factor 2 mrna-binding proteins (igf2bps): post-transcriptional drivers of cancer progression? Cell Mol Life Sci 70(15):2657–2675

    Article  CAS  PubMed  Google Scholar 

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Article  PubMed  Google Scholar 

  • Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J (2017) Pd-l1 expression in advanced nsclc: insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 112:200–215

    Article  PubMed  Google Scholar 

  • Camidge DR, Doebele RC, Kerr KM (2019) Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of nsclc. Nat Rev Clin Oncol 16(6):341–355

    Article  CAS  PubMed  Google Scholar 

  • Chen M, Wong C-M (2020) The emerging roles of n6-methyladenosine (m6a)deregulation in liver carcinogenesis. Mol Cancer 19(1):1–12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K (2014) Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14(8):535–546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M, Fenyö D, Moreira AL, Razavian N, Tsirigos A (2018) Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med 24(10):1559–1567

    Article  CAS  PubMed  Google Scholar 

  • Fakhrjou A, Niroumand-Oscoei SM, Somi MH, Ghojazadeh M, Naghashi S, Samankan S (2014) Prognostic value of tumor-infiltrating mast cells in outcome of patients with esophagus squamous cell carcinoma. J Gastrointest Cancer 45(1):48–53

    Article  CAS  PubMed  Google Scholar 

  • Fang J, Hu M, Sun Y, Zhou S, Li H (2020) Expression profile analysis of m6a rna methylation regulators indicates they are immune signature associated and can predict survival in kidney renal cell carcinoma. DNA Cell Biol 39(12):2194–2211

    Article  CAS  Google Scholar 

  • Gong PJ, Shao YC, Yang Y, Song WJ, He X, Zeng YF, Huang SR, Wei L, Zhang JW (2020) Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer. Front Oncol 10:578963. https://doi.org/10.3389/fonc.2020.578963

  • Guo W, Tan F, Huai Q, Wang Z, Shao F, Zhang G, Yang Z, Li R, Xue Q, Gao S et al (2021) Comprehensive analysis of pd-l1 expression, immune infiltrates, and m6a rna methylation regulators in esophageal squamous cell carcinoma. Front Immunol 12:669750

  • Gupta S, Coronado GD, Argenbright K, Brenner AT, Castãneda SF, Dominitz JA, Green B, Issaka RB, Levin TR, Reuland DS et al (2020) Mailed fecal immunochemical test outreach for colorectal cancer screening: summary of a centers for disease control and prevention-sponsored summit. CA Cancer J Clin 70(4):283–298

    Article  PubMed  PubMed Central  Google Scholar 

  • Herbst RS, Boshoffc M (2018) The biology and management of non small cell lung cancer. Nature 553(7689):446

    Article  CAS  PubMed  Google Scholar 

  • Hsu P-C, Jablons DM, Yang C-T, You L (2019) Epidermal growth factor receptor (egfr) pathway, yes-associated protein (yap) and the regulation of programmed death-ligand 1 (pd-l1) in non-small cell lung cancer (NSCLC). Int J Mol Sci 20(15):3821

    Article  CAS  PubMed Central  Google Scholar 

  • Hsu P-C, Yang C-T, Jablons DM, You L (2020) The crosstalk between src and hippo/yap signaling pathways in non-small cell lung cancer (nsclc). Cancers 12(6):1361

    Article  CAS  PubMed Central  Google Scholar 

  • Huang H, Weng H, Chen J (2020) m6a modification in coding and non-coding rnas: roles and therapeutic implications in cancer. Cancer Cell 37(3):270–288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G et al (2016) Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma. Cell 165(1):35–44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L et al (2019) m6a mrna methylation initiated by mettl3 directly promotes yap translation and increases yap activity by regulating the malat1-mir-1914-3p-yap axis to induce nsclc drug resistance and metastasis. J Hematol Oncol 12(1):1–22

    Article  CAS  Google Scholar 

  • Larsen TV, Hussmann D, Nielsen AL (2019) Pd-l1 and pd-l2 expression correlated genes in non-small-cell lung cancer. Cancer Commun 39(1):1–14

    Article  Google Scholar 

  • Li Y, Xiao J, Bai J, Tian Y, Qu Y, Chen X, Wang Q, Li X, Zhang Y, Xu J (2019) Molecular characterization and clinical relevance of m6a regulators across 33 cancer types. Mol Cancer 18(1):1–6

    Article  PubMed  PubMed Central  Google Scholar 

  • Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, Agrawal K, Gonzalez GM, Wang Y, Patel SP, Rana TM (2020a) ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A 117(33):20159–20170. https://doi.org/10.1073/pnas.1918986117

  • Li Y, Zheng J-N, Wang E-H, Gong C-J, Lan K-F, Ding X (2020b) The m6a reader protein ythdc2 is a potential biomarker and associated with immune infiltration in head and neck squamous cell carcinoma. PeerJ 8:10385

    Article  Google Scholar 

  • Li B, Zhu L, Lu C, Wang C, Wang H, Jin H, Ma X, Cheng Z, Yu C, Wang S et al (2021) circndufb2 inhibits non-small cell lung cancer progression via destabilizing igf2bps and activating anti-tumor immunity. Nat Commun 12(1):1–15

    CAS  Google Scholar 

  • Liu X, Qin J, Gao T, Li C, Chen X, Zeng K, Xu M, He B, Pan B, Xu X et al (2020) Analysis of mettl3 and mettl14 in hepatocellular carcinoma. Aging (albany NY) 12(21):21638

    Article  CAS  Google Scholar 

  • Liu Z, Wang T, She Y, Wu K, Gu S, Li L, Dong C, Chen C, Zhou Y (2021) N6-methyladenosine-modified circigf2bp3 inhibits cd8+ t-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of pd-l1 in non-small cell lung cancer. Mol Cancer 20(1):1–25

    Article  CAS  Google Scholar 

  • Ma J, Di Yang X-XM (2021) Immune infiltration-related n6-methyladenosine rna methylation regulators influence the malignancy and prognosis of endometrial cancer. Aging (albany NY) 13(12):16287

    Article  CAS  Google Scholar 

  • Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, Yuan W, Kan Q, Sun Z (2019) The interplay between m6a rna methylation and noncoding rna in cancer. J Hematol Oncol 12(1):1–15

    Article  CAS  Google Scholar 

  • Miao J, Hsu P-C, Yang Y-L, Xu Z, Dai Y, Wang Y, Chan G, Huang Z, Hu B, Li H et al (2017) Yap regulates pd-l1 expression in human nsclc cells. Oncotarget 8(70):114576

    Article  PubMed  PubMed Central  Google Scholar 

  • Mo P, Xie S, Cai W, Ruan J, Du Q, Ye J, Mao J (2020) N6-methyladenosine (m6a) rna methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules. J Int Med Res 48(9):0300060520951405

    Article  CAS  PubMed Central  Google Scholar 

  • Nagasaka M, Gadgeel SM (2018) Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther 18(1):63–70

    Article  CAS  PubMed  Google Scholar 

  • Qin Y, Li L, Luo E, Hou J, Yan G, Wang D, Qiao Y, Tang C (2020) Role of m6a rna methylation in cardiovascular disease. Int J Mol Med 46(6):1958–1972

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roundtree IA, Luo G-Z, Zhang Z, Wang X, Zhou T, Cui Y, He C (2017) YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife 6:e31311

    Article  PubMed  PubMed Central  Google Scholar 

  • Shi H, Zhao J, Han L, Xu M, Wang K, Shi J, Dong Z (2020) Retrospective study of gene signatures and prognostic value of m6a regulatory factor in non-small cell lung cancer using tcga database and the verification of fto. Aging (albany NY) 12(17):17022

    Article  CAS  Google Scholar 

  • Wang X, He C (2014) Reading rna methylation codes through methyl-specific binding proteins. RNA Biol 11(6):669–672

    Article  PubMed  PubMed Central  Google Scholar 

  • Wang X, Teng F, Kong L, Yu J (2016) Pd-l1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Y, Lu J-H, Wu Q-N, Jin Y, Wang D-S, Chen Y-X, Liu J, Luo X-J, Meng Q, Pu H-Y et al (2019) Lncrna linris stabilizes igf2bp2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer 18(1):1–18

    Article  PubMed  PubMed Central  Google Scholar 

  • Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, Jiang Z, Zhang Y, Xu G, Zhang J et al (2020) Mettl3-mediated m6a modification of hdgf mrna promotes gastric cancer progression and has prognostic significance. Gut 69(7):1193–1205

    Article  CAS  PubMed  Google Scholar 

  • Xu Y, Chen Y, Yao Y, Xie H, Lu G, Du C, Cheng J, Zhou J (2021) Virma contributes to non-small cell lung cancer progression via n6-methyladenosine-dependent dapk3 post-transcriptional modification. Cancer Lett 522:142–154

    Article  CAS  PubMed  Google Scholar 

  • Yan M, Sun L, Li J, Yu H, Lin H, Yu T, Zhao F, Zhu M, Liu L, Geng Q et al (2019) Rna-binding protein khsrp promotes tumor growth and metastasis in non-small cell lung cancer. J Exp Clin Cancer Res 38(1):1–17

    Article  Google Scholar 

  • Yuan Y, Du Y, Wang L, Liu X (2020) The m6a methyltransferase mettl3 promotes the development and progression of prostate carcinoma via mediating myc methylation. J Cancer 11(12):3588

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu X, Lang J (2017) Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 8(57):97671–97682 (PUBMED)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by Innovative Research Group Project of the National Natural Science Foundation of China (82073339; 62072058; 81974467), Funding of CSCO-Linghang (Y-2019AZMS-0002), and Scientific Projects of Shanxi Province (2021SF-044).

Author information

Author notes

  1. Xue Liu and Changsheng Ma contributed equally to this study.

Authors and Affiliations

  1. Department of Radiotherapy, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou, China

    Xue Liu, Zhiqiang Sun & Judong Luo

  2. Department of Radiotherapy, Graduate School of Dalian Medical University, Dalian, China

    Xue Liu

  3. Department of Radiotherapy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

    Changsheng Ma

  4. School of Computer Science and Technology, Nanjing Tech University, Nanjing, China

    Hui Liu

Authors
  1. Xue Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Changsheng Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhiqiang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Judong Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by [XL], [HL], [CM], [ZS] and [JL]. The first draft of the manuscript was written by [XL] and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Zhiqiang Sun or Judong Luo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (CSV 37 kb)

Supplementary file2 (DOCX 319 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Ma, C., Liu, H. et al. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer. J Cancer Res Clin Oncol 148, 2803–2814 (2022). https://doi.org/10.1007/s00432-022-04032-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-022-04032-y

Keywords

Search

Navigation